专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06531453B1 NKT cell activators containing &agr;-glycosylceramides 失效
标题翻译：含有α-糖基神经酰胺的NKT细胞活化剂
公开(公告)号：US06531453B1
公开(公告)日：2003-03-11
申请号：US09402785
申请日：1999-10-12
申请人： Masaru Taniguchi , Tetsu Kawano , Yasuhiko Koezuka
发明人： Masaru Taniguchi , Tetsu Kawano , Yasuhiko Koezuka
IPC分类号： A61K317028
CPC分类号： A61K31/7032 , A61K35/14 , C07H15/04 , C12N5/0646
摘要： An objective of the present invention is to provide NKT cell-activating agents, therapeutic agents for autoimmune diseases (for example, systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, encephalomyelitis, multiple sclerosis and human type I diabetes), and abortifacients. The medicinal compositions according to the present invention comprise &agr;-glycosylceramides of the following formula (I), or a salt or a solvate thereof as an active ingredient.
摘要翻译：本发明的目的是提供NKT细胞活化剂，用于自身免疫性疾病（例如，系统性红斑狼疮，系统性硬化症，溃疡性结肠炎，脑脊髓炎，多发性硬化和I型糖尿病）的治疗剂和流产者。根据本发明的药物组合物包含下式（I）的α-糖基神经酰胺或其盐或溶剂合物作为活性成分。

2. 发明授权

US06747010B2 NKT cell-activating agents containing &agr;-glycosylceramides 有权
标题翻译：含有α-糖基神经酰胺的NKT细胞活化剂
公开(公告)号：US06747010B2
公开(公告)日：2004-06-08
申请号：US10334861
申请日：2003-01-02
申请人： Masaru Taniguchi , Tetsu Kawano , Yasuhiko Koezuka
发明人： Masaru Taniguchi , Tetsu Kawano , Yasuhiko Koezuka
IPC分类号： A61K317028
CPC分类号： A61K31/7032 , A61K35/14 , C07H15/04 , C12N5/0646
摘要： An objective of the present invention is to provide NKT cell-activating agents, therapeutic agents for autoimmune diseases (for example, systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, encephalomyelitis, multiple sclerosis and human type I diabetes), and abortifacients. The medicinal compositions according to the present invention comprise &agr;-glycosylceramides of the following formula (I), or a salt or a solvate thereof as an active ingredient.
摘要翻译：本发明的目的是提供NKT细胞活化剂，用于自身免疫性疾病（例如，系统性红斑狼疮，系统性硬化症，溃疡性结肠炎，脑脊髓炎，多发性硬化和I型糖尿病）的治疗剂和流产者。根据本发明的药物组合物包含下式（I）的α-糖基神经酰胺或其盐或溶剂合物作为活性成分。

3. 发明授权

US10813950B2 Immunotherapy using allo-NKT cells, cells for immunotherapy in which alpha chain of t-cell receptor (TCR) gene has been rearranged to uniform Vα-Jα, and banking of NKT cells derived from said cells 有权
公开(公告)号：US10813950B2
公开(公告)日：2020-10-27
申请号：US13991059
申请日：2011-12-02
申请人： Masaru Taniguchi , Haruhiko Koseki , Hiroshi Watarai , Shin-ichiro Fujii
发明人： Masaru Taniguchi , Haruhiko Koseki , Hiroshi Watarai , Shin-ichiro Fujii
IPC分类号： A61K35/17 , C12N5/0783 , C07K14/725 , A61K45/06 , A61K31/7028 , C12N15/85
摘要： The present invention provides an agent for an immunocyte therapy, comprising an NKT cell obtained by differentiating in vitro a cell having the α-chain region of the T cell receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, wherein an administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of the NKT cell. In addition, the present invention provides a bank of a human cell or an NKT cell derived from said cell, wherein the α-chain region of a T cell receptor (TCR) gene has been rearranged to uniform Vα-Jα. The agent and cell bank of the present invention are useful for the prophylaxis and/or treatment of cancer, infection, an allergic disease or an autoimmune disease.

4. 发明申请

US20100129339A1 NKT CELL-STIMULATING AGENT FOR ADMINISTRATION THROUGH UPPER RESPIRATORY TRACT MUCOUS MEMBRANE 审中-公开
标题翻译： NKT细胞刺激剂通过上呼吸道麻醉膜进行管理
公开(公告)号：US20100129339A1
公开(公告)日：2010-05-27
申请号：US12089230
申请日：2006-10-06
申请人： Masaru Taniguchi , Shigetoshi Horiguchi , Yoshitaka Okamoto
发明人： Masaru Taniguchi , Shigetoshi Horiguchi , Yoshitaka Okamoto
IPC分类号： A61K45/00 , A61P37/04
CPC分类号： A61K35/15 , A61K2035/124 , C12N5/0639
摘要： The present invention provides an NKT cell stimulating agent containing antigen-presenting cells pulsed with an NKT cell ligand, to be administered submucosally in the upper airway. By submucosal administration in the upper airway, it is possible to stimulate NKT cells and stimulate immune reactions extremely efficiently with a small number of NKT cell ligand-pulsed antigen-presenting cells. By submucosal administration in the upper airway, NKT cells can be induced selectively in cervical lymph nodes.
摘要翻译：本发明提供含NKT细胞配体脉冲的抗原呈递细胞的NKT细胞刺激剂，其在上呼吸道中粘膜下施用。通过在上呼吸道中的粘膜下给药，可以刺激NKT细胞并且用少量NKT细胞配体脉冲的抗原呈递细胞极其有效地刺激免疫反应。通过在上呼吸道粘膜下给药，可以选择性诱导NKT细胞在子宫颈淋巴结中。

5. 发明申请

US20100062990A1 NOVEL PSEUDOGLYCOLIPID AND USE THEREOF 有权
标题翻译：新的PSEUDOGLYCOLIPID及其使用
公开(公告)号：US20100062990A1
公开(公告)日：2010-03-11
申请号：US12528232
申请日：2008-02-22
申请人： Takuya Tashiro , Kenji Mori , Ken-ichi Fuhshuku , Masaru Taniguchi , Ryusuke Nakagawa , Hiroshi Watarai
发明人： Takuya Tashiro , Kenji Mori , Ken-ichi Fuhshuku , Masaru Taniguchi , Ryusuke Nakagawa , Hiroshi Watarai
IPC分类号： A61K31/7028 , C07H15/00 , A61P35/00
CPC分类号： C07C235/08 , C07C233/18 , C07C233/36 , C07C323/41 , C07C2601/14
摘要： The invention provides a pseudoglycolipid effective for cancer treatment and the like and a novel synthesis intermediate therefor, as well as a medicament containing the pseudoglycolipid and the like. The inventive compound is represented by the formula (1), or a salt thereof, wherein each symbol is as defined in the specification.
摘要翻译：本发明提供了对癌症治疗等有效的假性糖脂及其中间体的新型合成物，以及含有假糖脂等的药物。本发明化合物由式（1）表示，或其盐，其中每个符号如说明书中所定义。

6. 发明申请

US20090215707A1 COMPOUND HAVING CYCLIC STRUCTURE AND USE THEREOF 有权
标题翻译：具有循环结构的化合物及其用途
公开(公告)号：US20090215707A1
公开(公告)日：2009-08-27
申请号：US11817616
申请日：2006-03-03
申请人： Ken-ichi Fuhshuku , Kenji Mori , Takuya Tashiro , Masaru Taniguchi , Ken-ichiro Seino
发明人： Ken-ichi Fuhshuku , Kenji Mori , Takuya Tashiro , Masaru Taniguchi , Ken-ichiro Seino
IPC分类号： A61K31/7056 , C07H15/26 , A61K31/7052 , A61P19/02 , A61P17/06 , A61P3/10 , A61P37/06 , A61P37/00
CPC分类号： C07D207/12 , C07D205/04 , C07D405/12 , C07F7/1804 , C07H15/26
摘要： The present invention relates to a compound represented by the following formula (1′) wherein R is an aldopyranose residue, R2 is a C2-18 hydrocarbon group optionally having substituent(s), R3 is an acyl group, X is an oxygen atom, a sulfur atom or —NH—, and p is an integer of 0-4, or a salt thereof.The compound of the present invention has a specific immunoregulatory ability, and is useful for the prophylaxis or treatment of autoimmune diseases and the like.
摘要翻译：本发明涉及由下式（1'）表示的化合物，其中R为吡喃葡萄糖残基，R2为任选具有取代基的C2-18烃基，R3为酰基，X为氧原子，硫原子或-NH-，p为0-4的整数，或其盐。本发明的化合物具有特异的免疫调节能力，可用于预防或治疗自身免疫性疾病等。

7. 发明申请

US20070104279A1 Modulating apparatus, mobile communication system, modulating method, and communication method 有权
标题翻译：调制装置，移动通信系统，调制方法和通信方法
公开(公告)号：US20070104279A1
公开(公告)日：2007-05-10
申请号：US10578228
申请日：2004-11-02
申请人： Masaru Taniguchi
发明人： Masaru Taniguchi
IPC分类号： H04L27/00
CPC分类号： H04L27/12 , H04L25/03834
摘要： An encoder encodes sound data and the like to generate a binary signal. A mapper converts the binary signal into a quaternary symbol and outputs the quaternary symbol. A base band filter includes a root raised cosine filter and a sinc filter. The base band filter blocks a predetermined frequency component of a symbol to shape the symbol into a waveform signal and outputs the waveform signal shaped. An FM modulator transmits a signal subjected to FM modulation according to a magnitude of an amplitude of a waveform signal to a receiving unit. When a symbol of ±3 is outputted from the mapper, a frequency shift of a signal transmitted from the FM modulator has a predetermined value in a range of ±0.822[kHz] to ±0.952[kHz]. This makes it possible to provide a modulating apparatus, a mobile communication system, a modulating method, and a communication method that use a modulating method that can conform to the FCC rule to be enforced in 2005 without using a linear power amplifier.
摘要翻译：编码器对声音数据等进行编码以产生二进制信号。映射器将二进制信号转换为四进制符号并输出四进制符号。基带滤波器包括根升余弦滤波器和正弦滤波器。基带滤波器阻挡符号的预定频率分量以将符号形成波形信号，并输出成形的波形信号。 FM调制器根据波形信号的幅度的大小向接收单元发送经受FM调制的信号。当从映射器输出±3的符号时，从FM调制器发送的信号的频移在±0.822 [kHz]至±0.952 [kHz]的范围内具有预定值。这使得可以提供一种调制装置，移动通信系统，调制方法和通信方法，该调制方法和通信方法使用可以符合FCC规则的调制方法，以便在2005年不使用线性功率放大器。

8. 发明授权

US5648332A Method of treating diabetes mellitus using variable .alpha. domain of T-cell receptor 失效
标题翻译：使用T细胞受体的可变α结构域治疗糖尿病的方法
公开(公告)号：US5648332A
公开(公告)日：1997-07-15
申请号：US318881
申请日：1994-10-20
申请人： Hiroshi Watanabe , Nobuyuki Yamagata , Masaru Taniguchi
发明人： Hiroshi Watanabe , Nobuyuki Yamagata , Masaru Taniguchi
IPC分类号： A61K38/00 , A61K39/00 , A61P37/06 , C07K14/725 , C12P21/02 , C12R1/91 , A61K38/17
CPC分类号： C07K14/7051 , A61K38/00 , A61K39/00 , C07K2319/00
摘要： A soluble T-cell receptor .alpha.-chain produced by suppressor T-cell. The said soluble T-cell receptor .alpha.-chain is useful as a prophylactic and therapeutic agent for autoimmune diseases generated to a wide variety of autoantigens irrespective of specificity to the said suppressor T-cell.
摘要翻译： PCT No.PCT / IB94 / 00029 Sec。 371日期：1994年10月20日 102（e）日期1994年10月20日PCT 1994年2月22日PCT PCT。公开号WO94 / 19470 日期1994年9月1日由抑制T细胞产生的可溶性T细胞受体α链。所述可溶性T细胞受体α链可用作对多种自身抗原产生的自身免疫疾病的预防和治疗剂，而不管对所述抑制T细胞的特异性。

9. 发明授权

US08551959B2 Glycolipid and use thereof 有权
标题翻译：糖脂及其用途
公开(公告)号：US08551959B2
公开(公告)日：2013-10-08
申请号：US12934515
申请日：2009-03-25
申请人： Takuya Tashiro , Kenji Mori , Masao Shiozaki , Ryusuke Nakagawa , Masaru Taniguchi , Hiroshi Watarai
发明人： Takuya Tashiro , Kenji Mori , Masao Shiozaki , Ryusuke Nakagawa , Masaru Taniguchi , Hiroshi Watarai
IPC分类号： A01N43/04 , A61K31/70 , A61K39/00 , C07H15/00 , C07H19/00
CPC分类号： C07H15/04
摘要： The invention provides a glycolipid effective for cancer treatment and the like and a synthetic intermediate therefor, as well as a medicament containing the glycolipid and the like. The glycolipid is represented by the formula (1) or a salt thereof
摘要翻译：本发明提供了对癌症治疗等有效的糖脂及其合成中间体，以及含有糖脂等的药物。糖脂由式（1）表示或其盐

10. 发明申请

US20130005669A1 NOVEL SYNTHETIC GLYCOLIPID AND USE THEREOF 有权
标题翻译：新型合成甘油脂及其用途
公开(公告)号：US20130005669A1
公开(公告)日：2013-01-03
申请号：US13577159
申请日：2011-02-04
申请人： Takuya Tashiro , Kenji Mori , Masao Shiozaki , Masaru Taniguchi , Hiroshi Watarai
发明人： Takuya Tashiro , Kenji Mori , Masao Shiozaki , Masaru Taniguchi , Hiroshi Watarai
IPC分类号： A61K31/7028 , A61P35/00 , C07H15/203 , A61P31/00 , C07H1/00 , C07H15/04 , C12N5/0783
CPC分类号： C07H15/04 , A61K31/7032
摘要： A compound represented by the following formula (1): wherein R1 is an aldopyranose residue wherein the 6-hydroxyl group is optionally alkylated, R2 is a C1-26 hydrocarbon group optionally having substituent(s), R3 is a hydrogen atom or a C1-26 hydrocarbon group optionally having substituent(s), R4 is a C1-21 hydrocarbon group optionally having substituent(s), X is an oxygen atom or —CH2—, and Y is —CH2—, —CH(OH)— or —CH═CH—, or a salt thereof is useful for the prophylaxis or treatment of cancer or infection, since it can preferentially induce production of IFN-γ of NKT cells.
摘要翻译：由下式（1）表示的化合物：其中R1是吡喃葡萄糖残基，其中6-羟基任选被烷基化，R 2是任选具有取代基的C 1-26烃基，R 3是氢原子或C 1 -26任选具有取代基的烃基，R4是任选具有取代基的C 1-12烃基，X是氧原子或-CH 2 - ，Y是-CH 2 - ， - CH（OH） - 或 -CH = CH-或其盐可用于预防或治疗癌症或感染，因为其可优先诱导NKT细胞的IFN-γ的产生。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式